ES2071995T3 - Composicion para la activacion de macrofagia. - Google Patents

Composicion para la activacion de macrofagia.

Info

Publication number
ES2071995T3
ES2071995T3 ES91908331T ES91908331T ES2071995T3 ES 2071995 T3 ES2071995 T3 ES 2071995T3 ES 91908331 T ES91908331 T ES 91908331T ES 91908331 T ES91908331 T ES 91908331T ES 2071995 T3 ES2071995 T3 ES 2071995T3
Authority
ES
Spain
Prior art keywords
compounds
macrophagy
activation
composition
phosphatidyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91908331T
Other languages
English (en)
Inventor
Gerald J Vosika
Dennis A Cornelius
John A Bennek
Karl E Swenson
Carl W Gilbert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImmunoTherapeutics Inc
Original Assignee
ImmunoTherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImmunoTherapeutics Inc filed Critical ImmunoTherapeutics Inc
Application granted granted Critical
Publication of ES2071995T3 publication Critical patent/ES2071995T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE DISACARIDODIPEPTIDOS LIOFILICOS NUEVOS. LOS COMPUESTOS DE LA INVENCION SE ENCAPSULAN, PREFERIBLEMENTE, EN LIPOSOMAS MULTILAMELARES, QUE SE PUEDEN FORMAR A PARTIR DE LA FOSFATIDIL COLINA Y DEL FOSFATIDIL GLICEROL. LOS COMPUESTOS SON EFICACES EN LA ACTIVACION DE MONOCITOS HUMANOS CON LA SUBSIGUIENTE DESTRUCCION DE LAS CELULAS TUMORALES. ESTOS COMPUESTOS TIENEN UNA TOXICIDAD ACEPTABLE A DOSIS HUMANAS ANTICIPADAS.
ES91908331T 1990-04-13 1991-03-12 Composicion para la activacion de macrofagia. Expired - Lifetime ES2071995T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/509,338 US5416070A (en) 1988-07-08 1990-04-13 Composition for macrophage activation

Publications (1)

Publication Number Publication Date
ES2071995T3 true ES2071995T3 (es) 1995-07-01

Family

ID=24026246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91908331T Expired - Lifetime ES2071995T3 (es) 1990-04-13 1991-03-12 Composicion para la activacion de macrofagia.

Country Status (10)

Country Link
US (1) US5416070A (es)
EP (1) EP0527803B1 (es)
JP (1) JPH05506657A (es)
AT (1) ATE120207T1 (es)
CA (1) CA2080002A1 (es)
DE (1) DE69108392T2 (es)
DK (1) DK0527803T3 (es)
ES (1) ES2071995T3 (es)
IE (1) IE74195B1 (es)
WO (1) WO1991016347A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292524A (en) * 1991-09-06 1994-03-08 California Institute Of Technology Blood platelet loaded with diagnostic or therapeutic-containing liposome or reconstituted Sendai virus
IT1252160B (it) * 1991-12-03 1995-06-05 Giuseppe Fichera Composizioni farmaceutiche contenenti il peptidoglicano del lactobacillus casei
FR2694559B1 (fr) * 1992-08-06 1994-10-28 Atta Nouveaux dérivés amphiphiles d'aminoacides ou de peptides, leur procédé de préparation et leur utilisation dans des préparations à usage biomédical.
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
WO2000058456A2 (en) 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
AU1226001A (en) * 1999-11-09 2001-06-06 Alcon Universal Limited Phospholipids of hydroxyeicosatetraenoic acid-like derivatives
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition
JP2013043885A (ja) * 2011-08-26 2013-03-04 Kansai Bunri Sogo Gakuen デヒドロアミノ酸含有グリセロール誘導体
AU2017225769B2 (en) 2016-03-02 2023-01-05 The Board Of Regents Of The University Of Texas System Sting activating nanovaccine for immunotherapy
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
US4186194A (en) * 1973-10-23 1980-01-29 Agence Nationale De Valorisation De La Recherche (Anvar) Water soluble agents effective as immunological adjuvants for stimulating, in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
FR2268531B1 (es) * 1974-04-25 1978-07-21 Anvar
US4370265A (en) * 1974-10-22 1983-01-25 Agence Nationale De Valorisation Water soluble agents effective as immunological adjuvants for stimulating in the host the immune response to various antigens and compositions, notably vaccines containing said water soluble agents
IL48325A (en) * 1974-10-22 1979-05-31 Anvar Immunological-free adjuvant compositions containing n-acetyl muramyl-alanyl-d-isoglutamine or n-acetyl-muramyl-l-alanyl-d-glutamicn acid
US4172125A (en) * 1974-10-22 1979-10-23 Agence Nationale De Valorisation De La Recherche (Anvar) Oil-free adjuvant compositions containing N-acetyl-muramyl-L-alanyl-D-glutamic acid and method of use
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
PH14773A (en) * 1976-01-01 1981-12-09 Kureha Chemical Ind Co Ltd Protein-bound polysaccharides
US4153684A (en) * 1976-03-10 1979-05-08 Agence Nationale De Valorisation De La Recherche (Anvar) Immunizing and anti-infectious adjuvant agents constituted by N-acetyl-muramyl-L-alanyl-D-glutamic acid derivatives
FR2369292A1 (fr) * 1976-11-02 1978-05-26 Anvar Agents adjuvants immunit
GB1563561A (en) * 1976-06-23 1980-03-26 Daiichi Seiyaku Co Muramyldipeptide derivatives and process for the preparation thereof
FR2368282A1 (fr) * 1976-10-22 1978-05-19 Anvar Adjuvant immunologique constitue par le p-amino-phenyl de n-acetyl-muramyl-l-alanyl-d-isoglutamine
SU727647A1 (ru) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US4397844A (en) * 1978-02-24 1983-08-09 Ciba-Geigy Corporation Antigen derivatives and processes for their preparation
FR2442241A2 (fr) * 1978-03-20 1980-06-20 Anvar Nouveaux composes esters de muramyl-peptide, leur preparation et les compositions pharmaceutiques les contenant, notamment sous forme de liposomes
FR2428050A1 (fr) * 1978-06-05 1980-01-04 Anvar Oligomeres de composes du type muramyl-peptide et medicaments les contenant
JPS5543030A (en) * 1978-09-21 1980-03-26 Dai Ichi Seiyaku Co Ltd Prophylactic and remedy for microbial infection disease
FR2446292A1 (fr) * 1979-01-12 1980-08-08 Anvar Muramyl-peptides fixes sur polymeres peptidiques et medicaments les contenant
US4256735A (en) * 1979-01-29 1981-03-17 Merck & Co., Inc. Immunologically active dipeptidyl saccharides and methods of preparation
FR2449697A1 (fr) * 1979-02-20 1980-09-19 Anvar Nouveaux muramyl-peptides substitues sur un azote peptidique et medicaments les contenant
US4391800A (en) * 1979-04-27 1983-07-05 Merck & Co., Inc. Immunologically active peptidyl disaccharides and methods of preparation
JPS5618996A (en) * 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
FI75578C (fi) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
JPS5943929B2 (ja) * 1979-08-13 1984-10-25 サッポロビール株式会社 多糖体ｒｂｓ物質，その製法およびそれを有効成分とする抗腫瘍性剤
US4357322A (en) * 1980-07-29 1982-11-02 Syntex (U.S.A.) Inc. Method of preventing, reducing or inhibiting inflammation
JPS58126797A (ja) * 1982-01-22 1983-07-28 Dainippon Pharmaceut Co Ltd ジサツカライドトリペプチド及びジサツカライドテトラペプチドの製法
JPS58198496A (ja) * 1982-05-14 1983-11-18 Dainippon Pharmaceut Co Ltd グルコサミニルムラミルペプチド誘導体
US4505899A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505900A (en) * 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4950645A (en) * 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation

Also Published As

Publication number Publication date
WO1991016347A1 (en) 1991-10-31
EP0527803B1 (en) 1995-03-22
DE69108392T2 (de) 1995-08-03
JPH05506657A (ja) 1993-09-30
IE74195B1 (en) 1997-07-16
DK0527803T3 (da) 1995-07-03
EP0527803A1 (en) 1993-02-24
CA2080002A1 (en) 1991-10-14
IE911101A1 (en) 1991-10-23
ATE120207T1 (de) 1995-04-15
US5416070A (en) 1995-05-16
DE69108392D1 (de) 1995-04-27

Similar Documents

Publication Publication Date Title
IT1203515B (it) Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
ATE423547T1 (de) N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform
FI964681A0 (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
ATE286718T1 (de) Temperatursensitive liposomale formulierung
CA2326761A1 (en) Antitumor agent
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ES2071995T3 (es) Composicion para la activacion de macrofagia.
ES2194114T3 (es) Formulaciones liposomicas de mitoxantrona.
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
DE69710065D1 (de) Androsten-derivate
BR9604950A (pt) Composição farmacêutica contendo n-clorofenil carbamatos n-clorofeniltiocarbamatos e derivados de n-fosfonoglicina para inibir o crescimento de cânceres e vírus em mamíferos
AR002987A1 (es) Composicion farmaceutica para el tratamiento de infecciones virales ocanceres o tumores, composicion de dosis unitaria que la comprende y uso para dicho tratamiento
DE68919225D1 (de) Zusammensetzung für makrophag-aktivierung.
SE9802937D0 (sv) Novel compounds
ES2108698T3 (es) Liposomas exentos de sustancias activas, para el tratamiento de aterosclerosis.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2128710T3 (es) Liposomas que contienen proteinas encapsuladas, procedimiento para su produccion asi como las preparaciones farmaceuticas y cosmeticas que contienen estos liposomas.
NZ335125A (en) Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
ES2059633T3 (es) 2-terc.-butil-4-cloro-5-(4-terc.-butilbenciltio)-3(2h)-piridazinona para la lucha contra los moluscos.
BR9812002A (pt) Compostos com efeito antiprimeiro-passe
IT1164363B (it) Procedimento terapeutico facente uso di liposomi imcorporati fruttosio 1,6 difosfato e procedimento per la preparazione degli stessi
IT8024104A0 (it) Derivato della lidocaina e composizioni terapeutiche che lo contengono come principio attivo.
MX9304283A (es) Derivados de tiadiazinona, procedimiento para su preparacion y preparacion farmaceutica que los con tienen.
AR230923A1 (es) Procedimiento de fabricacion de composiciones pesticidas para el tratamiento de madera,dichas composiciones y procedimiento para la proteccion de materiales de madera

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 527803

Country of ref document: ES